Kim Jenkins presentation at JMP was very good, especially considering the limited time allowed. Perhaps it was a little too techincal, but then again it is a very tecnical product. Sales and support personel have gone from three to twelve in the last 10 months. 23 current sites. No discussion of or projection for number of new installations. made a comment that sequential qurater over quarter growth was continuing, which hopefully bodes well for the most recent qurater when reported. Said future R&D is minimal.
MRIC ended Q1 with 23 sites...so, there was no new information in the presentation in terms of placements. The only thing that I saw that seemed different was that the sales & marketing staff is up to 12 people...if I recall correctly, Q1 ended with 10 people. So, look for sales to really start to ramp through year-end. It'll be interesting to see how effective sales have been for new sites when the Q2 earnings come out. ClearPoint is a very low capital expenditure for a hospital, saves a ton of time in the MRI / OR room for both doctor and patient...assuming physicians like using ClearPoint, this becomes a no-brainer purchase for the global hospital system. And, once the market starts picking up on ANY momentum in sales (placements / procedures), watch out...MRIC will move quickly higher. There's been a lot of insider buying lately as well. Will continue to add on any dips.